In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCsOn-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicityCombination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns Presenters:Catherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program: https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related